News

Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand
Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...
Forecasting The Future: 7 Analyst Projections For Eli Lilly
Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Eli Lilly LLY -1.05% ...
Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?
Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...
Eli Lilly is making it cheaper and easier to buy high doses of blockbuster weight-loss drug Zepbound
Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy.
India's response to obesity drug Mounjaro 'positive', says Eli Lilly
Mounjaro has sold more than 81,570 units in India, totalling about ₹23.94 crore ($2.76 million) as of May, with the drug ...
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
Lilly, Novo, and Amgen set for key obesity trial readouts at upcoming ADA event
Novo Nordisk (NVO), and Amgen (NASDAQ:AMGN) are scheduled to present major clinical trial readouts at the American Diabetes ...
Zacks Investment Research on MSN1d
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?
Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.